Drugs / BDB018
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04840394 | Jun 2021 → Mar 2024 | — | Eikon Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BDB018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04840394 ↗ |
| Action | Activate | “BDB018 is a next-generation Toll-like receptor (TLR) 7/8 agonist that activates the immune system.” NCT04840394 ↗ |